Alnylam Pharmaceuticals Inc. anticipates its drug vutrisiran will take a bigger chunk of the market for hereditary transthyretin-mediated (hATTR) amyloidosis after presenting long-term data in patients with polyneuropathy. The new 18-month data should also fulfill the requirements for the company to file for European Medicines Agency approval, whereas the drug is already under US Food and Drug Administration review based on 9-month data.
On 21 January, Alnylam presented 18-month data from the Phase III HELIOS-A study of vutrisiran at the Société Francophone du...